Avicenna journal of phytomedicine · 2026
Evaluation of the effects of Asparagus racemosus extract (ARova5X) supplementation on postmenopausal discomfort.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mishra Kumar Guru, Patnaik Nabnita, Mohapatra Adityananda, Pradhan Nihar Ranjan
Аннотация
OBJECTIVE: Menopause is a critical physiological transition often associated with a spectrum of health challenges such as sexual dysfunction, vasomotor symptoms, and increased oxidative stress. This study aimed to evaluate the efficacy of a hydroalcoholic extract of Asparagus racemosus root (ARova5X), standardized to contain 5% shatavarins, in improving health outcomes among postmenopausal women.
MATERIALS AND METHODS: A randomized, double-blind, placebo-controlled clinical trial was conducted at Apollo Hospitals, Hyderabad, India, during January 2024-2025. A total of 214 postmenopausal women were randomly assigned to receive either ARova5X (250 mg/day) or placebo for 90 days (n=107 per group). Outcome measures were assessed at baseline and post-intervention using validated tools including the Sexual Quotient-Female (SQ-F) questionnaire, the Female Intervention Efficacy Index (FIEI), oxidative stress markers, and anthropometric parameters. Primary endpoints included changes in sexual function, menopausal symptoms, oxidative stress, and weight-related measures.
RESULTS: Participants receiving ARova5X showed significant improvements in multiple domains of sexual function including desire (p<0.001), foreplay (p=0.002), arousal (p<0.001), and satisfaction (p=0.004) compared to the placebo group. Vaginal lubrication improved by 84.11% in the intervention group compared to 13.08% in the placebo group. Oxidative stress levels were markedly reduced, with 39.25% of women in the ARova5X group reaching minimal stress levels. Clinical obesity prevalence decreased from 42.99% to 29.91%. Menopausal symptoms such as hot flashes, fatigue, and irritability were also significantly alleviated.
CONCLUSION: ARova5X appears to be a safe, effective natural intervention for improving sexual health, reducing oxidative stress, and supporting weight management in postmenopausal women.
MATERIALS AND METHODS: A randomized, double-blind, placebo-controlled clinical trial was conducted at Apollo Hospitals, Hyderabad, India, during January 2024-2025. A total of 214 postmenopausal women were randomly assigned to receive either ARova5X (250 mg/day) or placebo for 90 days (n=107 per group). Outcome measures were assessed at baseline and post-intervention using validated tools including the Sexual Quotient-Female (SQ-F) questionnaire, the Female Intervention Efficacy Index (FIEI), oxidative stress markers, and anthropometric parameters. Primary endpoints included changes in sexual function, menopausal symptoms, oxidative stress, and weight-related measures.
RESULTS: Participants receiving ARova5X showed significant improvements in multiple domains of sexual function including desire (p<0.001), foreplay (p=0.002), arousal (p<0.001), and satisfaction (p=0.004) compared to the placebo group. Vaginal lubrication improved by 84.11% in the intervention group compared to 13.08% in the placebo group. Oxidative stress levels were markedly reduced, with 39.25% of women in the ARova5X group reaching minimal stress levels. Clinical obesity prevalence decreased from 42.99% to 29.91%. Menopausal symptoms such as hot flashes, fatigue, and irritability were also significantly alleviated.
CONCLUSION: ARova5X appears to be a safe, effective natural intervention for improving sexual health, reducing oxidative stress, and supporting weight management in postmenopausal women.